Evidence from the ToGA study presented at the American Society in return Clinical Oncology (ASCO) Annual Conclave in Orlando, Florida showed that adding trastuzumab to standard chemotherapy (capecitabine [Xeloda®] or intravenous 5-FU and cisplatin) prolongs the lives of patients with this quarrelsome cancer on usual by nearly 2.7 months to 13.8 months, a 26% increase in survival. Advanced gastric (stomach) cancer is associated with a poor projection; the median survival all together after diagnosis is about 10 months with currently available therapies.[i]
The international put a stop to III study shows that trastuzumab presupposed in combination with chemotherapy increases average survival by 26% in patients with HER2-positive advanced and inoperable stomach cancer compared to chemotherapy just. This syndicate is also in particular healthful to gastric cancer patients whose tumours express higher levels of HER2, increasing their median survival to 16 months.
Trastuzumab was the indistinct of intense media regard in 2005 when Patricia Hewitt, then Robustness Secretary, called for the sake of women with original stage HER2-positive breast cancer to be granted access to the treatment following evidence presented at ASCO showing that it offered unprecedented survival benefits.[ii]
“This is the initial antiquated that we have shown that adding a biological treatment to chemotherapy can improve survival in this patient team and represents a impressive advance in how we treat patients with this type of advanced gastric cancer” said UK investigator Prof. Jeff Evans, CRUK Professor of Translational Cancer Research, University of Glasgow. “Trastuzumab’s efficacy in these patients with gastric cancer demonstrates the important principle that targeting HER-2 thoroughgoing tumours is not restricted to breast cancer.”
Gastric cancer is the seventh most bourgeois basis of cancer-related expiration in the UK with over 8,000 creative cases diagnosed each year.[iii] Antiquated diagnosis is challenging because most patients do not show symptoms in the at place. Approximately 22% of stomach tumours are HER2-positive[iv]. This rebuke is the same in Europe and in Asia, where stomach cancer is markedly customary.
“Trastuzumab has brought significant promote to women suffering from HER2-dictatorial breast cancer. We are extraordinarily pleased to watch its formidable benefit extending to patients with bread basket cancer” commented William M. Burns, CEO of Roche’s Pharmaceuticals Division. “The targeted therapy trastuzumab discretion become the new standard of care and we can purloin an prominent contribution in serving these patients live longer.”
Trastuzumab is already showily established as the foundation of be enamoured of with a view patients with HER2-positive breast cancer and with it, based on the ToGA results, Roche will seek regulatory approvals notwithstanding the exhaust of trastuzumab in HER2-perfect advanced craving cancer.
In the ToGA study, no stylish or unexpected side effects were observed. The most frequent side effects were diarrhoea (4.8%) and febrile neutropenia (3.4%).
Down the ToGA study
ToGA is the first randomised Facet III trial investigating the use of trastuzumab in patients with inoperable locally advanced, habitual and/or metastatic HER2-functional gastric cancer. 3883 patients were tested proper for HER2-positive tumours and 594 patients with HER2-emphatic blight were enrolled into the mug up. The explanation for conducting this trial was based on the knowledge that the targeted group therapy trastuzumab has demonstrated unprecedented efficacy in the treatment of HER2-positive bust cancer. In addition, the overexpression of HER2 was also observed in yearning cancer. A targeted anti-cancer therapy is a type of medication that blocks the advancement of cancer cells by interfering with specific molecules which cause a cancer to attraction to.
In the ToGA read, patients were randomised to receive one of the following regimens as their pre-eminent plumb b in agreement of treatment:
– A fluoropyrimidine (capecitabine or intravenous 5-FU) and cisplatin every 3 weeks fit 6 cycles. Most (87%) patients were receiving capecitabine and cisplatin as chemotherapy
– Trastuzumab 6mg/kg every 3 weeks until sequence in society with a fluoropyrimidine and cisplatin for 6 cycles
The simple aim of the writing-room was to demonstrate distinction in total survival of the trastuzumab-containing treatment arm compared to the chemotherapy alone arm. The pre-planned interim investigation was triggered by the event of 347 events. Backup endpoints championing the study included progression-above survival, all-embracing feedback rate, duration of effect, safeness and quality of energy. In the ToGA learning, no imaginative or unexpected side effects were observed. The most common side effects were diarrhoea (4.8%) and febrile neutropenia (3.4%). In return whole survival, the Hazard Ratio was 0.74 (CI 0.6, 0.9) with a effectively significant p-value of p=0.0046. Herceptin increased the median overall survival set by 2.7 months to 13.8 months. The response rate was increased with Herceptin from 34.5 % to 47.3%. Patients with tumours exhibiting high levels of HER2 sage even greater benefit from the addition of trastuzumab.
On touching Herceptin (trastuzumab)
Trastuzumab is a humanised antibody, designed to target and bung up the occupation of HER2, a protein produced by a specific gene with cancer-causing dormant. The mode of action of trastuzumab is one of a kind in that it activates the body’s immune system and suppresses HER2 to quarry and break up the excrescence. Trastuzumab has demonstrated unprecedented efficacy in treating both primeval and advanced (metastatic) HER2-promising heart cancer. Delineated on its own as monotherapy as plainly as in combination with or following prevailing chemotherapy, trastuzumab has been shown to put response rates, bug-untrammelled survival and overall survival while maintaining quality of life in women with HER2-positive breast cancer.
Trastuzumab received assent to for point in the European Union for advanced (metastatic) HER2-positive breast cancer in 2000, and for originally HER2-realistic core cancer in 2006. In the advanced stage set, trastuzumab is sporadically approved for use as a initially-line therapy in syndicate with paclitaxel where anthracyclines are unsuitable, as maiden-information group therapy in combination with docetaxel, and as a single intermediary in third-line remedy. It is also approved for use in mixture with an aromatase inhibitor for the treatment of post-menopausal patients with HER2 and hormone receptor co-positive metastatic breast cancer. In the early setting, trastuzumab is approved after use following standard (adjuvant) chemotherapy. Trastuzumab is not approved for smoke in yearning cancer.
Trastuzumab is marketed in the United States by Genentech, in Japan by Chugai and internationally by Roche. Since 1998, trastuzumab has been worn to treat nearly 600,000 patients with HER2-positive core cancer worldwide.
Regarding Xeloda (capecitabine)
– Capecitabine is a targeted oral chemotherapy that uniquely activates the cancer-killing agent 5-FU (5-fluorouracil) directly inside the cancer cells[v]
– As an oral tablet with equivalent efficacy to IV 5-FU/FA, patients can take capecitabine in their own home, reducing the number of hospital visits
– Licensed in more than 100 countries worldwide, capecitabine has over ten years proven clinical know-how providing an chattels and flexible treatment option to as a remainder 1.5 million people with cancer. In the UK capecitabine is currently indicated for
– Phase III (Dukes’ situation C) colon cancer
- Monotherapy as adjuvant treatment following surgery
– Metastatic (advanced) colorectal cancer
- Monotherapy
- In combination with any chemotherapy in all lines of treatment
– Advanced gastric (stomach) cancer
- In organization with platinum-based chemotherapy first ancestry
– Locally advanced or metastatic breast cancer
- Monotherapy first hire in patients after failure of taxanes and an anthracycline-containing chemotherapy regimen or for whom anthracycline cure is not indicated
- In combination with docetaxel in patients after decay of cytotoxic chemotherapy. Previous psychotherapy should have included an anthracycline
References
[i] Hosokawa et al. Covet-term outcomes of patients with metastatic gastric cancer after approve S-1 monotherapy. J Gastroenterol 2007; 42:533-538
[ii] Department of Health. Convenient at http://www.dh.gov.uk/en/News/Speeches/Speecheslist/DH_4121929. Accessed May 2009
[iii] Cancer Explore UK. Bear cancer statistics. At one’s disposal at http://www.cancerresearchuk.org. Accessed May 2009
[iv] Bang YJ et al. ASCO 2008 (poster no. 4526)
[v] Maroun JA. Capecitabine in the governance of colorectal cancer. Skilled Rev Anticancer Ther 2001; 1:327-33
Source
Roche
Landscape drug information on Herceptin; Xeloda.
0 Responses
Stay in touch with the conversation, subscribe to the RSS feed for comments on this post.
You must be logged in to post a comment.